Eralfon: 6 x 2000iu composition
The solution consists of alpha epoetin (REPOETHIN-SP - human erythropoietin, recombinant) and auxiliary substances - albumin solution, sodium citrate pentasecylhydrate or sodium citrate dihydrate, water for injection, sodium chloride, citric acid monohydrate.
Glycoprotein epoetin alfa - the main component of Eralfona, promotes stimulation of erythropoiesis through activation of erythrocyte maturation. Epoetin is produced by animal cells with a built-in human erythropoietin gene.
The drug raises the level of hematocrit, hemoglobin, improves heart function and overall blood supply to body tissues. Eralfon is effective in anemia caused by kidney pathology.
Indications for use
The medication is recommended for anemia caused by kidney failure, chronic lymphocytic leukemia, antitumor therapy, HIV infection, myeloma, rheumatoid arthritis, and non-Hodgkin's lymphomas.
The drug is recommended to be administered to premature infants for the treatment of anemia and its prevention.
Eralfon should be used before extensive operations with hematocrit 33-39% or expected loss of blood 0,9-1,8 l.
Mode of application
Solution Eralfon need to enter a sc or IV. Intravenously, the dose should be 20-30% higher than for injections.
Patients with kidney disease Eralfon introduced after dialysis. The solution is administered 3 r./week. n / to 30 IU / kg, in / in to 50 IU / kg. During treatment, depending on the increase in hematocrit, the dose is increased or decreased by 1.5 times. The dose for the maintenance phase of therapy is selected individually.
Children with hemodialysis appoint 50 units / kg 3 rubles / week, increase the dose can be 25 units / kg 1 rub. / Month. The maintenance dose for children less than 10 kg of weight is 75-150 ED / kg, 10-30 kg - 60-150 ED / kg, 30 kg and above - 30-100 ED / kg.
Adults in pre-dialysis therapy are prescribed Eralfon 3 rubles / week. 50 ED / kg with an allowable increase of 25 units / kg 1 p./month. Supportive therapy is 17-33 U / kg 3 r. / Week.
Oncological with large tumors of Eralfon it is recommended to administer 150 IU / kg 3 r. / Week. In the absence of positive dynamics after a monthly treatment, the dose is increased to 300 IU / kg. After an ineffective monthly use of an increased dose, the use of Eralfon should be discontinued. After reaching hemoglobin at 120 g / l, the solution is administered at a dose of 1/4 lower than that used previously. After the chemotherapy, Eralfon is administered a minimum of 1 month.
In case of HIV infection, 100 IU / kg 3 r. / Week for 2 months is administered. At a low rate of recovery of laboratory blood counts, the dose of Eralfon can be increased by 50-100 IU / kg 3 r. / Week not more often than 1 r./month. If the therapy is ineffective at 300 IU / kg 3 r. / Week. further treatment is meaningless. Supportive therapy is performed at a dose below the therapeutic dose by 25%.
For the treatment of anemia, patients with non-Hodgkin's lymphomas, lymphatic leukemia and myeloma disease are shown the administration of Eralfon sc, 100 IU / kg 3 r. / Week. The dose can be increased 1 r./month. With the introduction of 600 IU / kg / week. and the absence of a therapeutic effect of further treatment by Eralfon is inexpedient.
Preterm infants Eralfon is administered from the 6th day of birth of sc to 200 IU / kg 3 r. / Week. not more than 6 weeks.
Patients in the collection of autologous blood solution is administered after the procedure for collecting blood. The solution is administered at 600 ME / kg 2 r./week.
Patients who are not engaged in autologous blood collection before the operation are shown injections of 600 IU / kg of 1 rub. / Week - 21, 14, 7th before and on the day of the operation. With a shorter preoperative period, the medication is administered at 300 IU / kg 1 r./day - on the day of the manipulation and 4 days after it.
When the solution is administered, manifestations of influenza-like syndrome, chills, fever, and headache are allowed.
Treatment with Eralfon may be accompanied by dose-dependent hypertension, thrombocytosis, a decrease in the level of ferritin, hyperkalemia, hyperphosphatemia.
Very rarely treatment is aggravated by aplasia of erythrocyte sprouts, hypertensive crisis, rapid increase in pressure with symptoms of brain damage and convulsions, thrombosis of arteriovenous fistula or shunt, exacerbation of porphyria.
Rarely, the administration of a medication can trigger an allergy with cutaneous manifestations or angioedema.
In the place of introduction of Eralfona, burning, soreness, hyperthermia is possible.
Eralfon it is forbidden to use people with an allergy to the composition of the solution.
The drug is contraindicated in patients with a history of partial red cell aplasia, provoked by the management of any erythropoietin.
The solution is prohibited for use in uncontrolled hypertension, the inability to conduct effective anticoagulant therapy, severe arterial diseases, acute myocardial infarction and stroke.
With caution, Eralfon is recommended for use in thrombosis, cancer, epileptic seizures, sickle cell anemia, iron deficiency and B9, B12 vitamins, porphyria, liver disease, thrombocytosis.
Eralfon: 6 x 2000iu
- Product Code: EPO
- Availability: In Stock